Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: A comparison between two Asian studies and four Western studies

Cancer Medicine

Volumn 1, Issue 2, 2012, Pages 198-206

  Sugihara, Kenichi ^a   Ohtsu, Atsushi ^b   Shimada, Yasuhiro ^c   Mizunuma, Nobuyuki ^d   Gomi, Katsushige ^e   Lee, Po Huang ^f   de Gramont, Aimery ^g   Rothenberg, Mace L ^h   André, Thierry ^g   Brienza, Silvano ⁱ   Goldberg, Richard M ^j  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

^e YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g HÔPITAL SAINT ANTOINE   (France)

^h VANDERBILT INGRAM CANCER CENTER   (United States)

ⁱ DEBIOPHARM SA   (Switzerland)

^j OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

Colorectal cancer; Ethnic difference; FOLFOX4; Neurotoxicity; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; ASIAN; CANCER PATIENT; CAUCASIAN; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; HUMAN; INCIDENCE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RACE DIFFERENCE; SENSORY NEUROPATHY; TREATMENT DURATION; WESTERN HEMISPHERE;

EID: 84907063467     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.25     Document Type: Article

References (34)

1. de Gramont, A., A. Figer, M. Seymour, et al. 2000. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18:2938-2947.
2. Goldberg, R. M., D. J. Sargent, R. F. Morton, et al. 2004. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22:23-30.
3. Rothenberg, M. L., A. M. Oza, R. H. Bigelow, et al. 2003. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J. Clin. Oncol. 21:252.
4. Rothenberg M. L., A. M. Oza, B. Burger, et al. 2003. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc. Am. Soc. Clin. Oncol. 22:252. Abstract 1011.
5. Lim, E. H., R. S. C. Lim, T. S. Wu, and H. L. Kong. 2003. Oxaliplatin/fluorouracil/leucovorin in advanced colorectal carcinoma: an Asian experience. Ann. Pharmacother. 37:1909-1912.
6. Yang, T.-S., J.-S. Chen, R. Tang, et al. 2003. Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. Chemotherapy 49:194-199.
7. Yamada, Y., A. Ohtsu, N. Boku, et al. 2006. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer. Jpn. J. Clin. Oncol. 36:218-223.
8. Suenaga M., T. Nishina, I. Hyodo, et al. 2008. A feasibility study of oxaliplatin (L-OHP) in combination with infusional 5-FU/LV (FOLFOX4 regimen) for advanced colorectal cancer. Jpn. J. Cancer Chemother. 35:255-260 (in Japanese).
9. André, T., C. Boni, L. Mounedji-Boudiaf, et al. 2004. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 350:2343-2351.
10. André, T., C. Boni, M. Navarro, et al. 2009. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J. Clin. Oncol. 27:3109-3116.
11. Lee, P.-H., Y.-S. Park, J.-F. Ji, Y.-T. Fu, and V. Ratanatharathorn. 2009. Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: the MASCOT study. Asia-Pac. J. Clin. Oncol. 5:101-110.
12. Saltz, L. B., S. Clarke, F. Diaz-Rubio, et al. 2008. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol. 26:2013-2019.
13. de Gramont, A., E. Van Cutsem, J. Tabernero, et al. 2011. AVANT: results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer. Proc. Am. Soc. Clin. Oncol. 29(Suppl 4):139. Abstract 362.
14. Bokemeyer, C., I. Bondarenko, A. Makhson, et al. 2009. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27:663-671.
15. Douillard, J.-Y., S. Siena, J. Cassidy, et al. 2010. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28:4697-4705.
16. Allegra, C. J., G. Yothers, M. J. O'Connell, et al. 2009. Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. J. Clin. Oncol. 27:3385-3390.
17. Pasetto, L. M., M. R. D'Andrea, E. Rossi, and S. Monfardini. 2006. Oxaliplatin-related neurotoxicity: how and why? Crit. Rev. Oncol. Hematol. 59:159-168.
18. Argyriou, A. A., P. Polychronopoulos, G. Iconomou, E. Chroni, and H. P. Kalofonos. 2008. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev. 34:368-377.
19. Maindrault-Goebel, F., T. André, C. Tournigand, et al. 2005. Allergic-type reactions to oxaliplatin: retrospective analysis of 42 patients. Eur. J. Cancer 41:2262-2267.
20. Saif, M. W. 2006. Hypersensitivity reactions associated with oxaliplatin. Expert Opin. Drug Saf. 5:687-694.
21. Grolleau, F., L. Gamelin, M. Boisdron-Celle, B. Lapied, M. Pelhate, and E. Gamelin. 2001. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J. Neurophysiol. 85:2293-2297.
22. + channel function in vivo. Clin. Cancer Res. 12:4481-4484.
23. Cavaletti, G., G. Tredici, M. G. Petruccioli, et al. 2001. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur. J. Cancer 37:2457-2463.
24. Jamieson, S. M. F., J. Subramaniam, J. J. Liu, et al. 2009. Oxaliplatin-induced loss of phosphorylated heavy neurofilament subunit neuronal immunoreactivity in rat DRG tissue. Mol. Pain 5:66-74.
25. Gamelin, L., M. Boisdron-Celle, R. Delva, et al. 2004. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin. Cancer Res. 10:4055-4061.
26. Grothey, A., D. A. Nikcevich, J. A. Sloan, 2011. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J. Clin. Oncol. 29:421-427.
27. Sanoff, H. K., D. J. Sargent, E. M. Green, H. L. McLeod, and R. M. Goldberg. 2009. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J. Clin. Oncol. 27:4109-4115.
28. Laiyemo, A. O., C. Doubeni, P. F. Pinsky, et al. 2010. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J. Natl. Cancer Inst. 102:538-546.
29. Sugihara, K., A. Ohtsu, Y. Shimada, et al. 2012. Safety analysis of FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies. Clin. Colorectal Cancer 11:127-137.
30. Department of Health and Human Services, Food and Drug Administration, Rockville, MD, U.S.A. 2010. Guidance for industry: S9 nonclinical evaluation for anticancer pharmaceuticals. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM085389.pdf (accessed 16 February 2012).
31. 105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin. Cancer Res. 12:3050-3056.
32. McLeod, H. L., D. J. Sargent, S. Marsh, et al. 2010. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J. Clin. Oncol. 28:3227-3233.
33. Gamelin, L., O. Capitain, A. Morel, et al. 2007. Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin. Cancer Res. 13:6359-6368.
34. Wolf, S., D. Barton, L. Kottschade, A. Grothey, and C. Loprinzi. 2008. Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur. J. Cancer 44:1507-1515.